Effects of Magnesium and Spinning Training on Echocardiographic, Inflammatory, and Aerobic Outcomes
17 de junio de 2026 actualizado por: Hikmet Kocaman, Karamanoğlu Mehmetbey University
Effects of Magnesium Supplementation and Spinning Training on Cardiac Function, Oxidative Stress, Inflammation, and Aerobic Capacity
Regular aerobic exercise may improve cardiorespiratory fitness while modulating systemic inflammation and oxidative stress. Spinning, as a structured indoor cycling modality, provides a practical aerobic exercise model with adjustable intensity and duration, but its effects on redox balance, inflammatory status, aerobic capacity, and cardiac functional parameters may vary according to individual recovery and nutritional status. Magnesium is an essential micronutrient involved in energy metabolism, muscle contraction-relaxation, ion regulation, and inflammatory and oxidative pathways; therefore, magnesium use may be relevant to exercise adaptation and recovery.
This study aims to evaluate the associations of magnesium use and spinning training with oxidative stress, inflammation, aerobic capacity, and cardiac parameters. In this context, biochemical markers related to oxidative/antioxidant status and inflammation, aerobic performance indicators, and echocardiographic cardiac function parameters will be assessed together. The study is expected to provide real-world evidence on whether magnesium use in individuals participating in spinning training is associated with more favorable redox, inflammatory, aerobic, and cardiac profiles.
Descripción general del estudio
Estado
Inscripción por invitación
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Estimado)
48
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Karaman, Turquía (Türkiye), 70100
- Karamanoğlu Mehmetbey University, Faculty of Sport Sciences
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Sí
Descripción
Inclusion Criteria:
- Self-identified male participants
- Aged 18 to 30 years
- Physically active individuals
- Participants who are eligible to participate in a structured spinning training program
- Participants with available baseline and follow-up assessments for biochemical, aerobic capacity, and cardiac function parameters
Exclusion Criteria:
- Presence of any chronic systemic disease
- Acute infection during the study period
- Regular use of anti-inflammatory or antioxidant medications
- Use of antioxidant or ergogenic supplements other than magnesium
- Any cardiovascular, musculoskeletal, or neurological condition that may limit participation in spinning training
- Missing baseline or follow-up outcome data
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Control group
Participants in this arm will not receive any exercise training, magnesium supplementation, or placebo intervention during the study period.
They will continue their usual daily routines and will undergo the same baseline and follow-up assessments as the intervention groups.
|
|
|
Comparador activo: Spinning Training Group
Participants in this arm will participate in a structured spinning training program during the study period.
No magnesium supplementation or placebo will be administered.
Baseline and follow-up assessments will include oxidative stress, inflammatory, aerobic capacity, and cardiac function parameters.
|
Participants will participate in a structured spinning training program during the study period.
The program will consist of supervised indoor cycling sessions performed at a planned frequency, duration, and intensity.
|
|
Experimental: Spinning + Magnesium Group
Participants in this arm will participate in a structured spinning training program and receive magnesium supplementation during the study period.
Baseline and follow-up assessments will include oxidative stress, inflammatory, aerobic capacity, and cardiac function parameters.
|
Participants will participate in a structured spinning training program during the study period.
The program will consist of supervised indoor cycling sessions performed at a planned frequency, duration, and intensity.
Participants will receive oral magnesium supplementation during the study period in addition to the structured spinning training program.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Maximal Oxygen Uptake (VO₂max)
Periodo de tiempo: Baseline and 6 weeks
|
Maximal oxygen uptake (VO₂max, mL/kg/min) will be assessed using a graded exercise test.
The change in VO₂max from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Serum Magnesium Concentration
Periodo de tiempo: Baseline and 6 weeks
|
Serum magnesium concentration (mg/dL) will be measured using standard laboratory methods.
The change in serum magnesium levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Total Antioxidant Status (TAS)
Periodo de tiempo: Baseline and 6 weeks
|
Serum total antioxidant status (TAS, mmol Trolox equivalent/L) will be measured using commercially available assay kits.
The change in TAS from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Total Oxidant Status (TOS)
Periodo de tiempo: Baseline and 6 weeks
|
Serum total oxidant status (TOS, μmol H₂O₂ equivalent/L) will be measured using commercially available assay kits.
The change in TOS from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Paraoxonase-1 Activity (PON1)
Periodo de tiempo: Baseline and 6 weeks
|
Serum paraoxonase-1 (PON1, U/L) activity will be determined using spectrophotometric methods.
The change in PON1 activity from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Arylesterase Activity (ARE)
Periodo de tiempo: Baseline and 6 weeks
|
Serum arylesterase (ARE, kU/L) activity will be determined using spectrophotometric methods.
The change in ARE activity from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Periodo de tiempo: Baseline and 6 weeks
|
Serum high-sensitivity C-reactive protein (hs-CRP, mg/L) concentration will be measured using standard laboratory methods.
The change in hs-CRP levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Interleukin-6 (IL-6)
Periodo de tiempo: Baseline and 6 weeks
|
Serum interleukin-6 (IL-6, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods.
The change in IL-6 levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Tumor Necrosis Factor-Alpha (TNF-α)
Periodo de tiempo: Baseline and 6 weeks
|
Serum tumor necrosis factor-alpha (TNF-α, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods.
The change in TNF-α levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Serum Potassium Concentration
Periodo de tiempo: Baseline and 6 weeks
|
Serum potassium concentration (mmol/L) will be measured using standard biochemical methods.
The change in serum potassium levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Serum Calcium Concentration
Periodo de tiempo: Baseline and 6 weeks
|
Serum calcium concentration (mg/dL) will be measured using standard biochemical methods.
The change in serum calcium levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)
Periodo de tiempo: Baseline and 6 weeks
|
Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP, pg/mL) concentration will be measured using immunoassay methods.
The change in NT-proBNP levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Left Ventricular Ejection Fraction (LVEF)
Periodo de tiempo: Baseline and 6 weeks
|
Left ventricular ejection fraction (LVEF, %) will be assessed by transthoracic echocardiography.
The change in LVEF from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Şemsi Gül Yılmaz Kocaman, PhD, Karamanoğlu Mehmetbey University
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Chavarrias M, Carlos-Vivas J, Collado-Mateo D, Perez-Gomez J. Health Benefits of Indoor Cycling: A Systematic Review. Medicina (Kaunas). 2019 Aug 8;55(8):452. doi: 10.3390/medicina55080452.
- Tarsitano MG, Quinzi F, Folino K, Greco F, Oranges FP, Cerulli C, Emerenziani GP. Effects of magnesium supplementation on muscle soreness in different type of physical activities: a systematic review. J Transl Med. 2024 Jul 5;22(1):629. doi: 10.1186/s12967-024-05434-x.
- Sireno L, Dimauro I, Caporossi D. Reactive oxygen species in exercise biology: from adaptive stress response to cell signaling and beyond. Free Radic Biol Med. 2026 Mar 1;245:447-462. doi: 10.1016/j.freeradbiomed.2025.12.044. Epub 2026 Jan 2. No abstract available.
- Reno AM, Green M, Killen LG, O'Neal EK, Pritchett K, Hanson Z. Effects of Magnesium Supplementation on Muscle Soreness and Performance. J Strength Cond Res. 2022 Aug 1;36(8):2198-2203. doi: 10.1519/JSC.0000000000003827. Epub 2020 Oct 1.
- Feng W, Wang Y, Gu X, Yu D, Liu Z. Exercise as a modulator of systemic inflammation and oxidative stress biomarkers across clinical and healthy populations: an umbrella meta-analysis. BMC Sports Sci Med Rehabil. 2025 Nov 28;17(1):360. doi: 10.1186/s13102-025-01327-8.
- Dominguez LJ, Veronese N, Ragusa FS, Baio SM, Sgro F, Russo A, Battaglia G, Bianco A, Barbagallo M. The Importance of Vitamin D and Magnesium in Athletes. Nutrients. 2025 May 13;17(10):1655. doi: 10.3390/nu17101655.
- Battista RA, Foster C, Andrew J, Wright G, Lucia A, Porcari JP. Physiologic responses during indoor cycling. J Strength Cond Res. 2008 Jul;22(4):1236-41. doi: 10.1519/JSC.0b013e318173dbc4.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
1 de junio de 2026
Finalización primaria (Estimado)
15 de agosto de 2026
Finalización del estudio (Estimado)
20 de agosto de 2026
Fechas de registro del estudio
Enviado por primera vez
5 de junio de 2026
Primero enviado que cumplió con los criterios de control de calidad
17 de junio de 2026
Publicado por primera vez (Actual)
23 de junio de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
23 de junio de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
17 de junio de 2026
Última verificación
1 de junio de 2026
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 02-2026/29
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Descripción del plan IPD
Individual participant data will not be shared because the dataset contains participant-level health and performance records.
All results will be reported in aggregate form, and confidentiality will be maintained in accordance with applicable data protection regulations.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .